Gastrointestinal cancer: CDX2: prognostic marker for high-risk colon cancer


improvements in disease-free survival (DFS) outcomes have been observed in patients with stage III colon cancer, owing to the availability of new adjuvant treatment regimens. However, no reliable single biomarker exists that enables stratification of patients with highrisk, stage II disease for appropriate therapy. Patients with stage II colon cancer are… (More)
DOI: 10.1038/nrclinonc.2016.18


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Blog articles referencing this paper

Slides referencing similar topics